TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12526285
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg) at 4 weeks
Study: 2248062
Drug: Moclobemide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (100 mg)
Study: 2248062
Drug: Moclobemide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (200 mg, 3 times daily)
Study: 2248062
Drug: Alcohol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.6 g/l)
Study: 23183751
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (1200 IU), folic acid (0.5 mg), vitamin B12 (0.5 mg), vitamin B6 (50 mg), and calcium carbonate (456 mg) (group A)
Study: 21721475
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (standard multivitamin formula with phytonutrients); details on dosage and duration not specified.
Study: 17922899
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Nicotinell lozenge
Study: 6138071
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg midazolam
Study: 1587067
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ephedrine
Study: 3886400
Drug: Urapidil 30
Normalized name: urapidil 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 30 mg b.i.d.
Study: 3886400
Drug: Clonidine 0.075-0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.075-0.15 mg b.i.d.
Study: 29468978
Drug: Echium amoenum
Normalized name: Echium plantagineum seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echium amoenum compound syrup (EACS)
Study: 29468978
Drug: Citalopram tablet
Normalized name: Citalopram Tablets
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram tablet
Study: 27175680
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) 0.25 μg/kg/h diluted to 100 mL in 0.9% saline
Study: 16418872
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg t.i.d.
Study: 18477491
Drug: Conventional regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional regimen (13 cycles with 21 days of treatment + 7 days without hormones)
Study: 18477491
Drug: Extended-cycle regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-cycle regimen (four extended cycles with 84 days of continuous administration of EE/DNG, followed by a hormone-free interval of 7 days)
Study: 15816785
Drug: mirtazapine 30
Normalized name: mirtazapine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirtazapine 30 mg
Study: 15816785
Drug: escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 10 mg and 20 mg
Study: 8777303
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg bd + Amoxicillin 750 mg bd + Metronidazole 500 mg bd
Study: 1647185
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with 30 mg/m2 cisplatin once a week
Study: 1647185
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with 6 mg/m2 cisplatin daily
Study: 24557088
Drug: Dutasteride (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (4 mg)
Study: 23251997
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous lidocaine infusion of 2 mg/kg/h
Study: 15777307
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 microg) as adjuvant for lidocaine (40 ml of lidocaine at 10 mg/ml)
Study: 15777307
Drug: Lidocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (40 ml of lidocaine at 10 mg/ml) with saline
Study: 31996186
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg bovine lactoferrin (bLF) in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier
Study: 31996186
Drug: No bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No bovine lactoferrin (bLF) with daily feeds
Study: 11434597
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha (IFN-α) alone (group A)
Study: 11434597
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha (IFN-α) with ribavirin (group B)
Study: 11732520
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg) given 3 hours before induction of anaesthesia
Study: 11732520
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg) given 1 hour before induction of anaesthesia
Study: 11732520
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nothing with 10 ml water)
Study: 7014656
Drug: Pentazocine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (50 mg)
Study: 1550907
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg t.i.d.
Study: 1550907
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg b.i.d.
Study: 1550907
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg t.i.d.
Study: 3926229
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with iodine-131 or carbimazole in hyperthyroid patients
Study: 3926229
Drug: Thyroxine replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine replacement therapy in hypothyroid patients
Study: 3926229
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of thyroxine replacement therapy in hypothyroid patients
Study: 10102947
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy with amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d., and lansoprazole 30 mg b.d.
Study: 10102947
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy (same as above) for re-treatment of patients who failed 1-day treatment.
Study: 31793529
Drug: Frinozol nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frinozol nasal spray (Phenylephrine + Cetyrizine)
Study: 28202383
Drug: Tailored program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored program of physical therapy
Study: 21949991
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg Alprostadil injection by vein, once a day for 14 days (Group B)
Study: 11564829
Drug: IL-10 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-10 administered subcutaneously for 28 days
Study: 9563670
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate Aqueous Nasal Spray (FPANS)
Study: 28320220
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (Yiqiqubai granule + 308-nm excimer laser)
Study: 24930619
Drug: Radioembolization with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioembolization with yttrium-90 resin microspheres followed by sorafenib (200 mg twice daily escalating to 400 mg twice daily)
Study: 24930619
Drug: Sorafenib only
Normalized name: Sorafenib only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib only (matching dose schedule to the intervention arm)
Study: 16877419
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg three times a day for two periods of 5 days)
Study: 10718775
Drug: Subcutaneous infusion
Normalized name: subcutaneous infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusion morphine (5 mg)
Study: 1525789
Drug: Cisapride 5
Normalized name: cisapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 5 mg TID
Study: 3885848
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of intradermal BCG vaccine
Study: 26677350
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (30 g)
Study: 16497643
Drug: Non-treatment (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment (control group) at 3 years
Study: 11565517
Drug: Irbesartan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (300 mg daily)
Study: 3327677
Drug: Moduretic (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moduretic (after dose increase)
Study: 9103485
Drug: Hydrocodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone (10 mg, 15 mg, and 22.5 mg p.o.) after placebo or quinidine (100 mg) pretreatment
Study: 9103485
Drug: Quinidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (100 mg) pretreatment
Study: 7942523
Drug: t‐PA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA plus saline solution (group 1)
Study: 3035878
Drug: Zimeldine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimeldine, 100 mg, b.i.d., n = 40
Study: 3035878
Drug: Maprotiline, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline, 75 mg, b.i.d., n = 35
Study: 29196928
Drug: L-thyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine treatment (LT4 group)
Study: 16214379
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy vs Exercise therapy
Study: 15330820
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg intramuscularly
Study: 9203174
Drug: Steroid-resistant nephrotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-resistant nephrotic syndrome
Study: 3275568
Drug: Rifampin (300-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (300-450 mg/day)
Study: 30109672
Drug: HD-MA (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-MA (high-dose methotrexate plus cytarabine)
Study: 11264734
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated)
Study: 12359687
Drug: Olanzapine augmentation
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine augmentation for 8 weeks
Study: 12359687
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration for 8 weeks
Study: 23460714
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus gefitinib 250 mg/d, orally (arm B)
Study: 10941967
Drug: Partially vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially vegetable fat milk (3.5 g/dL fat; 50% vegetable fat: rapeseed oil)
Study: 10941967
Drug: Full vegetable-fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full vegetable-fat milk (3.5 g/dL fat; 100% vegetable fat: palm, coconut, and soy oil)
Study: 10941967
Drug: Standard-fat milk
Normalized name: MILK FAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-fat milk (3.5 g/dL cow's milk fat)
Study: 8473716
Drug: Imipramine 150
Normalized name: imipramine pamoate 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 150 mg/day
Study: 7734470
Drug: Imipramine 10
Normalized name: trimipramine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 10 mg/day (control)
Study: 25632806
Drug: Pinaverium (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium (50 mg, 3 times/day)
Study: 15116084
Drug: Red carrots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red carrots (5 mg/day)
Study: 15116084
Drug: Tomato paste
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato paste (5 mg/day)
Study: 15116084
Drug: Tomato paste
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato paste plus white carrots (5 mg/day)
Study: 11297716
Drug: Cognitive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive intervention designed to reduce anxiety/distress responses to the doxapram injection
Study: 1903918
Drug: Flecainide (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (0.15 mg.kg‐1.h‐1 after a loading dose of 2 mg.kg‐1)
Study: 1903918
Drug: Digoxin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (10 micrograms.kg‐1 for 12 hours, then 0.25 mg.24 h‐1)
Study: 26363825
Drug: Mifepristone (25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (25mg every 12h for 3 days and 600μg buccal misoprostol on the morning of the fourth day)
Study: 20939675
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) plus clomiphene citrate (CC)
Study: 20939675
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus clomiphene citrate (CC)
Study: 15163387
Drug: Perindopril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril treatment group
Study: 6761890
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and dipyridamole (ASA + DPM)
Study: 6761890
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and dipyridamole (ASA + DPM) post-operative therapy
Study: 27231549
Drug: Four-drug combination
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug combination therapy (low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine)
Study: 27231549
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination therapy (tacrolimus, mycophenolate mofetil, and corticosteroids)
Study: 7671566
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium intake (260 mmol/day) with arginine vasopressin infusion (2 fmol min‐1 kg‐1)
Study: 7671566
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium intake (20 mmol/day) with arginine vasopressin infusion (2 fmol min‐1 kg‐1)
Study: 2111414
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of PSK
Study: 7244752
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine (various doses)
Study: 7244752
Drug: Optimal epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal epinephrine therapy
Study: 30552589
Drug: Articaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine group - inferior alveolar nerve block with lignocaine (2%) adrenaline (1:80000) + Buccal infiltration with articaine (4%) with adrenaline (1:100000)
Study: 27538109
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel sheeting applied to one foot scar for 12 weeks
Study: 24433223
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin
Study: 20513728
Drug: resolution of
Normalized name: Revolution
Approvals — FDA: no, EMA: no, PMDA: no
Description: resolution of ST elevation in aVR to <1 mm after fibrinolytic therapy
Study: 20513728
Drug: new ST
Normalized name: BENZALKONIUM CHLORIDE 1 g in 500 mL EXTRACORPOREAL LIQUID [BZK NEW STERILIZATION FORMULA AITI-BACTERIAL MULTI-PURPOSESPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: new ST elevation > or =1 mm after fibrinolytic therapy
Study: 11004863
Drug: Mitogenic stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitogenic stimulation of peripheral blood lymphocytes by PHA (1 microgram/ml)
Study: 11777366
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of prednisone
Study: 23126609
Drug: Butorphanol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0.1 mg/kg bwt)
Study: 23126609
Drug: Butorphanol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0.05 mg/kg bwt)
Study: 6814669
Drug: Saline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.5 ml)
Study: 19501213
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (both high and low estrogen)
Study: 15567797
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fu needling and electric acupuncture
Study: 11028934
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir prophylaxis
Study: 8310723
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acid mixture (10 g/h)
Study: 8283363
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered placebo
Study: 8283363
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (in recurrent wheezing group)
Study: 8283363
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered albuterol
Study: 8283363
Drug: Nebulized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized saline solution
Study: 3051529
Drug: Identical-appearing placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical-appearing placebo tablets twice daily for up to 3 years
Study: 11441422
Drug: Ecopipam (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam (100 mg p.o.)
Study: 9743296
Drug: Reinduction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinduction therapy with the same cytostatic treatment (5-FU/LV or 5-FU/LLV) administered at 100 mg m(‐2) day(‐1) by i.v. bolus injection, followed by 5-FU 400 mg m(‐2) day(‐1) given as a 2-h infusion for 5 consecutive days at 4-week intervals x 6 or until tumor progression.
Study: 24131861
Drug: Focal psychodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal psychodynamic therapy
Study: 25865660
Drug: Standard portion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard portion size of ice cream
Study: 25865660
Drug: Larger portion
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger portion size of ice cream
Study: 21112641
Drug: Antenatal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal intervention (nine‐unit self‐guided workbook with weekly telephone support)
Study: 17380232
Drug: RIX4414 live
Normalized name: HUMAN ROTAVIRUS A TYPE G1P(8) STRAIN RIX4414 LIVE ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 live attenuated human rotavirus vaccine (10^5.8 FFU)
Study: 14997172
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with mirtazapine
Study: 11711508
Drug: Felodipine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (2.5, 5, or 10 mg once daily)
Study: 9025120
Drug: Biological parents
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological parents of ADHD boys
Study: 9025120
Drug: Biological parents
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological parents of comparison boys
Study: 3414992
Drug: 0.5% tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% tetracaine (15 mg)
Study: 3414992
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (15 mg)
Study: 29649764
Drug: Intranasal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal progesterone (9 mg MPP22)
Study: 29649764
Drug: Intranasal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal progesterone (4.5 mg MPP22)
Study: 23613962
Drug: Carvedilol (CARV)
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol (CARV) after saline infusion
Study: 12600850
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (energy-free soup with 50 g carbohydrate)
Study: 11268452
Drug: Cisplatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (5 x 20 mg/m2) over 5 days
Study: 11268452
Drug: Cisplatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (1 x 50 mg/m2) plus ifosfamide (4 g/m2) as a single-day infusion
Study: 11268452
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with carboplatin (3 x 500 mg/m2) and ifosfamide (3 x 4 g/m2) over three days
Study: 27832753
Drug: Oxytocin augmentation
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin augmentation
Study: 29096522
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine by infusion
Study: 19455984
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy
Study: 15115904
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (carvedilol + enalapril)
Study: 12239447
Drug: Vinblastine (VBL)
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinblastine (VBL) 0.15 mg/kg i.v. every 2 weeks and Interferon-gamma (IFN-gamma) 100 microg s.c. 3 times weekly (Trial 1)